Goldman Sachs Group, Inc. (The) set a $36.00 price target on Pfizer, Inc. (NYSE:PFE) in a report issued on Wednesday. The firm currently has a neutral rating on the biopharmaceutical company’s stock.

A number of other brokerages also recently issued reports on PFE. Deutsche Bank AG set a $38.00 price target on Pfizer and gave the stock a buy rating in a research report on Wednesday, October 11th. BMO Capital Markets set a $37.00 price target on Pfizer and gave the stock a buy rating in a research report on Tuesday, October 10th. Barclays PLC set a $38.00 price target on Pfizer and gave the stock a buy rating in a research report on Wednesday, October 11th. Zacks Investment Research downgraded Pfizer from a buy rating to a hold rating in a research report on Wednesday, October 11th. Finally, Jefferies Group LLC set a $38.00 price target on Pfizer and gave the stock a neutral rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $38.35.

Pfizer (NYSE PFE) opened at $35.55 on Wednesday. The stock has a market capitalization of $211,428.25, a P/E ratio of 14.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01. The company has a current ratio of 1.34, a quick ratio of 1.06 and a debt-to-equity ratio of 0.58. Pfizer has a 1 year low of $29.90 and a 1 year high of $36.78.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.67% and a net margin of 18.69%. Pfizer’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.61 earnings per share. equities analysts forecast that Pfizer will post 2.59 EPS for the current fiscal year.

WARNING: This piece was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/goldman-sachs-group-inc-the-analysts-give-pfizer-inc-pfe-a-36-00-price-target/1679380.html.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.60%. Pfizer’s dividend payout ratio (DPR) is 79.01%.

In other Pfizer news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the completion of the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last three months, insiders have sold 389,621 shares of company stock valued at $13,298,598. 0.06% of the stock is owned by insiders.

A number of hedge funds have recently bought and sold shares of the business. Northstar Group Inc. increased its stake in Pfizer by 0.4% during the second quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 35 shares during the last quarter. Peregrine Asset Advisers Inc. grew its stake in shares of Pfizer by 0.5% in the second quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC grew its stake in shares of Pfizer by 0.8% in the second quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 50 shares in the last quarter. River Wealth Advisors LLC grew its stake in shares of Pfizer by 0.3% in the second quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock valued at $531,000 after buying an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC grew its stake in shares of Pfizer by 0.5% in the second quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock valued at $402,000 after buying an additional 57 shares in the last quarter. 69.01% of the stock is owned by institutional investors.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.